US OptionsDetailed Quotes
GPCR240719C65000
- 0.09
- -0.48-84.21%
15min DelayClose Jul 16 16:00 ET
0.15High0.09Low
0.15Open0.57Pre Close3 Volume600 Open Interest65.00Strike Price33.00Turnover198.52%IV45.75%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type0.0294Delta0.0079Gamma496.22Leverage Ratio-0.0652Theta0.0001Rho14.61Eff Leverage0.0028Vega
Structure Therapeutics Stock Discussion
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US)$ Orforglipron and $Structure Therapeutics(GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
On fire
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
JMP Securities Reiterates Market Outperform on Structure Therapeutics, Maintains $91 Price Target - moomoo
No comment yet